116 related articles for article (PubMed ID: 26175400)
21. Tumor antigen-based immunotherapy and immunoprevention of cancer.
Ryan SO; Gantt KR; Finn OJ
Int Arch Allergy Immunol; 2007; 142(3):179-89. PubMed ID: 17106205
[TBL] [Abstract][Full Text] [Related]
22. [Development of novel immunotherapy targeting cancer immune evasion].
Tamada K
Gan To Kagaku Ryoho; 2014 Sep; 41(9):1062-5. PubMed ID: 25248888
[TBL] [Abstract][Full Text] [Related]
23. [Adjuvant BCG immunotherapy in the management of superficial bladder tumors].
Somogyi L; Szántó A; Polyák L; Baranyay F; Drinóczy M
Orv Hetil; 1993 Aug; 134(34):1851-6. PubMed ID: 8355975
[TBL] [Abstract][Full Text] [Related]
24. Prospects of combinatorial synthetic peptide vaccine-based immunotherapy against cancer.
Arens R; van Hall T; van der Burg SH; Ossendorp F; Melief CJ
Semin Immunol; 2013 Apr; 25(2):182-90. PubMed ID: 23706598
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of bacille Calmette-Guérin immunotherapy predicted by expression of antigen-presenting molecules and chemokines.
Videira PA; Calais FM; Correia M; Ligeiro D; Crespo HJ; Calais F; Trindade H
Urology; 2009 Oct; 74(4):944-50. PubMed ID: 19428084
[TBL] [Abstract][Full Text] [Related]
26. Immunoprophylactic intravesical application of bacillus Calmette-Guerin after transurethral resection of superficial bladder cancer.
Librenjak D; Situm M; Eterovic D; Dogas Z; Gotovac J
Croat Med J; 2003 Apr; 44(2):187-92. PubMed ID: 12698510
[TBL] [Abstract][Full Text] [Related]
27. Cancer immunotherapy with surgery.
Orita K; Miwa H; Mannami T; Konaga E; Yumura M
Acta Med Okayama; 1977 Aug; 31(4):217-34. PubMed ID: 145159
[TBL] [Abstract][Full Text] [Related]
28. New strategies in advanced cervical cancer: from angiogenesis blockade to immunotherapy.
Tewari KS; Monk BJ
Clin Cancer Res; 2014 Nov; 20(21):5349-58. PubMed ID: 25104084
[TBL] [Abstract][Full Text] [Related]
29. Therapy for minimal residual tumor disease: beta-galactosylceramide inhibits the growth of recurrent HPV16-associated neoplasms after surgery and chemotherapy.
Símová J; Indrová M; Bieblová J; Mikysková R; Bubeník J; Reinis M
Int J Cancer; 2010 Jun; 126(12):2997-3004. PubMed ID: 19739073
[TBL] [Abstract][Full Text] [Related]
30. [Vaccination strategies for solid tumors--fundamentals, limitations, and recent results].
Atanackovic D
Ther Umsch; 2004 Jun; 61(6):389-96. PubMed ID: 15253165
[TBL] [Abstract][Full Text] [Related]
31. Approaches to improve development methods for therapeutic cancer vaccines.
Ogi C; Aruga A
Immunol Lett; 2015 Apr; 164(2):100-8. PubMed ID: 25746315
[TBL] [Abstract][Full Text] [Related]
32. [Immunotherapy targeting cancer stem cells].
Kawakami Y; Matsushita M; Ueda R; Tsukamoto N; Ohta S
Nihon Rinsho; 2012 Dec; 70(12):2142-6. PubMed ID: 23259387
[TBL] [Abstract][Full Text] [Related]
33. Reversal of tumor-mediated immunosuppression.
Vieweg J; Su Z; Dahm P; Kusmartsev S
Clin Cancer Res; 2007 Jan; 13(2 Pt 2):727s-732s. PubMed ID: 17255301
[TBL] [Abstract][Full Text] [Related]
34. Overview of tumor cell-based vaccines.
Copier J; Dalgleish A
Int Rev Immunol; 2006; 25(5-6):297-319. PubMed ID: 17169778
[TBL] [Abstract][Full Text] [Related]
35. MUC1 as a target antigen for cancer immunotherapy.
Acres B; Limacher JM
Expert Rev Vaccines; 2005 Aug; 4(4):493-502. PubMed ID: 16117706
[TBL] [Abstract][Full Text] [Related]
36. Osteosarcoma. Results of treatment employing adjuvant immunotherapy.
Eilber FR; Townsend C; Morton DL
Clin Orthop Relat Res; 1975 Sep; (111):94-100. PubMed ID: 1057467
[TBL] [Abstract][Full Text] [Related]
37. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
Bodey B; Siegel SE; Kaiser HE
Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
[TBL] [Abstract][Full Text] [Related]
38. Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naïve prostate cancer.
Simons JW; Carducci MA; Mikhak B; Lim M; Biedrzycki B; Borellini F; Clift SM; Hege KM; Ando DG; Piantadosi S; Mulligan R; Nelson WG
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3394-401. PubMed ID: 16740763
[TBL] [Abstract][Full Text] [Related]
39. [Repeated yearly BCG treatment in superficial bladder cancer].
Somogyi L; Török A; Bors G; Drinóczy M; Horváth R
Orv Hetil; 1989 Mar; 130(13):671-3. PubMed ID: 2726237
[TBL] [Abstract][Full Text] [Related]
40. IL-13 receptor-directed cancer vaccines and immunotherapy.
Nakashima H; Husain SR; Puri RK
Immunotherapy; 2012 Apr; 4(4):443-51. PubMed ID: 22512637
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
